The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer
April 19th 2016Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).
Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines
April 4th 2016William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.
Neratinib Application Delayed for HER2+ Breast Cancer
Puma Biotechnology announced that it plans to delay the submission of a new drug application until mid-2016 for neratinib as an extended adjuvant treatment for patients with HER2-positive early breast cancer following a trastuzumab-based regimen.
Key Studies Help Chart Course in HER2-Positive Breast Cancer
Among the bright spots in the treatment of patients with breast cancer are the successes achieved in the management of HER2-positive disease. And, therapeutic options are continuing to expand, owing to the advent of novel anti-HER2–targeted agents and multitargeted HER2 receptor blockade.
Advances on the Horizon for ER+/HER2+ Breast Cancer, But Questions Remain
February 26th 2016Sunil Verma, MD, discusses advancing treatment in ER+/HER2+ breast cancer, specific therapies that should be considered for this subgroup, upcoming clinical trials, and the biggest challenges and questions that remain in this setting.
Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer
February 25th 2016Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.
Neratinib Improves DFS in HER2-Positive Breast Cancer
Treatment with the tyrosine kinase inhibitor neratinib demonstrated a 2-year disease-free survival rate of 93.9% in patients with early-stage HER2-positive breast cancer, representing a 33% improvement compared with placebo.
ASCO Guideline Clarifies Biomarker Assay Use in Adjuvant Breast Cancer Care
February 8th 2016ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.